1143522-26-2

Upstream product

• 1143519-20-3 6-tert-butyl-4-ethoxy-nicotinic acid ethyl ester 
• 1415334-30-3 sodium 6-tert-butyl-4-ethoxynicotinate 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 1190194-62-7 C₇H₁₄N₂O*ClH 
• 1143519-19-0 ethyl 6-(tert-butyl)-4-oxo-1,4-dihydropyridine-3-carboxylate 

Relevant academic research and scientific papers

Efficient large-scale synthesis of a 2,4,5-triarylimidazoline MDM2 antagonist

An improved, kilogram-scale synthesis of a triarylimidazoline MDM2 antagonist is reported. The nicotinic acid component was prepared in three steps from ethyl 2-dimethylaminomethylene-3-oxo-butyrate. The coupling of the nicotinic acid with the meso-diamine selectively produced the monoamide which was cyclized in the presence of p-TSA/pyridine to give the imidazoline core. Phosgenation using bis(trichloromethyl) carbonate provided the key carbamoyl chloride intermediate, which was coupled with the side-chain amine, followed by chiral resolution with (R)-camphorsulfonic acid to give the final API.

CHIRAL CIS-IMIDAZOLINES

There are provided compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are as herein described, processes for obtaining said compounds and pharmaceutical preparations containing them. These compounds are useful as anticancer agents, in particular as agents in the treatment of solid tumors.